Back to Journals » OncoTargets and Therapy » Volume 11

Investigation of LEP and LEPR polymorphisms with the risk of hepatocellular carcinoma: a case–control study in Eastern Chinese Han population

Authors Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Liu C, Liu L, Chen Y

Received 12 October 2017

Accepted for publication 16 February 2018

Published 11 April 2018 Volume 2018:11 Pages 2083—2089

DOI https://doi.org/10.2147/OTT.S153931

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Justinn Cochran

Peer reviewer comments 3

Editor who approved publication: Dr Samir Farghaly


Sheng Zhang,1,* Jiakai Jiang,1,* Zhan Chen,2,* Yafeng Wang,3 Weifeng Tang,2 Chao Liu,4 Longgen Liu,5 Yu Chen6–8

1Department of General Surgery, Changzhou No. 3 People’s Hospital, Changzhou, Jiangsu Province, 2Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, 3Department of Cardiology, The People’s Hospital of Xishuangbanna Dai Autonomous Prefecture, Jinghong, Yunnan Province, 4Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, 5Department of Liver Disease, Changzhou No. 3 People’s Hospital, Changzhou, Jiangsu Province, 6Cancer Bio-immunotherapy Center, 7Department of Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, 8Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian Province, China

*These authors contributed equally to this work

Background: Leptin (LEP) and LEP receptor (LEPR) polymorphisms may be associated with the development of cancer.
Methods: In this study, we selected five functional LEP and LEPR single-nucleotide polymorphisms (SNPs) and conducted a case–control study to determine the relationship of LEP and LEPR polymorphisms with hepatocellular carcinoma (HCC) risk in Eastern Chinese Han population. There were 584 HCC cases and 923 cancer-free controls included in our study. HCC patients and controls were fully matched by age and sex. SNPscan™ genotyping method was used to analyze the genotyping of LEP rs2167270 G>A, rs7799039 A>G, LEPR rs6588147 G>A, rs1137100 G>A, and rs1137101 G>A SNPs.
Results: We found that LEP rs7799039 A>G and rs2167270 G>A polymorphisms were associated with the susceptibility of HCC in this population (LEP rs7799039 A>G: GG vs AA: adjusted odds ratio [OR]=2.03, 95% CI, 1.22–3.38, P=0.006 and GG vs AA/AG: adjusted OR=1.97, 95% CI, 1.20–3.22, P=0.007; rs2167270 G.A: AA vs GG: adjusted OR=2.03, 95% CI, 1.10–3.75, P=0.024 and AA vs GG/GA: adjusted OR=2.01, 95% CI, 1.10–3.68, P=0.023). However, LEPR rs6588147 G>A polymorphism decreased the risk of HCC (GA vs GG: adjusted OR=0.62, 95% CI, 0.45–0.86, P=0.005 and AA/GA vs GG: adjusted OR=0.64, 95% CI, 0.47–0.88, P=0.007).
Conclusion:
This case–control study highlights that LEP rs7799039 A>G and rs2167270 G>A polymorphisms increase the susceptibility to HCC; however, LEPR rs6588147 G>A polymorphism may be a protective factor for HCC in Eastern Chinese Han population.

Keywords: LEP, LEPR, polymorphism, hepatocellular carcinoma, risk, single nucleotide polymorphism, hepatitis B virus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]